There is growing evidence to suggest that changes in expression of the adapter protein p130cas (Cas) in breast tumors may contribute to cancer progression and poor prognosis. In human breast tumors, Cas overexpression is correlated with a high probability of recurrence and a high incidence of intrinsic resistance to the antiestrogen tamoxifen. Antiestrogen resistance is also evident in cultured breast cancer cells that overexpress either Cas or its binding partner AND-34/BCAR3. Cas is comprised of multiple structural domains, each of which has the capacity to interact with a different array of proteins and thus promote potentially distinct functional outcomes. We hypothesize that overexpression of Cas or AND-34 activates signaling pathways through interactions with a defined subset of these proteins, ultimately leading to antiestrogen resistance and changes in cell physiology that are associated with aggressive tumor behavior and poor prognosis. This hypothesis will be tested in Aim 1 by identifying domains and downstream effectors of Cas and AND-34 that function to promote antiestrogen resistance, and investigating how these pathways coordinate with or override estrogen receptor functions during this process.
In Aim 2, we will test whether Cas overexpression in cells that serve as models for early-stage breast cancer can induce changes in cell physiology and morphology that coincide with the acquisition of a more aggressive growth and invasion phenotype. Conversely, we will also test whether inhibition of Cas expression or function in cells that serve as models for late-stage breast cancer reverses some of the deleterious phenotypes exhibited by these cells. The potential functional contribution of proteins known to bind to domains that are implicated in the studies described above will be pursued in the context of each of the two Specific Aims. However, in those instances where a domain is implicated that does not have a known binding partner, or when none of the known binding proteins are found to play a role, attempts will be made in Aim 3 to identify additional binding partners and test whether they function in these pathways. Completion of this work will open new avenues of investigation into such areas as the development of molecular screens for predicting responses to tamoxifen treatment, the design of strategies for enhancing the efficacy of tamoxifen in intrinsically resistant patients, and the application of novel molecular approaches to slow tumor progression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA096846-05
Application #
7245014
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Woodhouse, Elizabeth
Project Start
2003-07-01
Project End
2009-04-30
Budget Start
2007-07-01
Budget End
2009-04-30
Support Year
5
Fiscal Year
2007
Total Cost
$237,732
Indirect Cost
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Cross, A M; Wilson, A L; Guerrero, M S et al. (2016) Breast cancer antiestrogen resistance 3-p130(Cas) interactions promote adhesion disassembly and invasion in breast cancer cells. Oncogene 35:5850-5859
Zhao, Yingshe; Kumbrink, Joerg; Lin, Bor-Tyh et al. (2013) Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression. Carcinogenesis 34:2880-90
Wilson, Ashley L; Schrecengost, Randy S; Guerrero, Michael S et al. (2013) Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. PLoS One 8:e65678
Guerrero, Michael S; Parsons, J Thomas; Bouton, Amy H (2012) Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton. Genes Cancer 3:371-81
Schuh, Natasha R; Guerrero, Michael S; Schrecengost, Randy S et al. (2010) BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling. J Biol Chem 285:2309-17
Ta, Huy Q; Thomas, Keena S; Schrecengost, Randy S et al. (2008) A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res 68:8796-804
Riggins, Rebecca B; Schrecengost, Randy S; Guerrero, Michael S et al. (2007) Pathways to tamoxifen resistance. Cancer Lett 256:1-24
Schrecengost, Randy S; Riggins, Rebecca B; Thomas, Keena S et al. (2007) Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res 67:6174-82
Cowell, L N; Graham, J D; Bouton, A H et al. (2006) Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway. Oncogene 25:7597-607
Riggins, Rebecca B; Thomas, Keena S; Ta, Huy Q et al. (2006) Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66:7007-15